StreetInsider.com News Articles

Form EFFECT Edesa Biotech, Inc.

Tue, 14 Jul 2026 06:03:00 -0400

si-local-file:///var/storage/secattach/20260714/26764250.html

Form EFFECT Edesa Biotech, Inc.

Tue, 14 Jul 2026 06:03:00 -0400

si-local-file:///var/storage/secattach/20260714/26764250.html

Form 424B3 Edesa Biotech, Inc.

Mon, 13 Jul 2026 16:15:00 -0400

si-local-file:///var/storage/secattach/20260713/26762639.html

Form 424B3 Edesa Biotech, Inc.

Mon, 13 Jul 2026 16:15:00 -0400

si-local-file:///var/storage/secattach/20260713/26762639.html

Form 4 Edesa Biotech, Inc. For: Jul 02 Filed by: Nijhawan Pardeep

Thu, 02 Jul 2026 17:06:00 -0400

si-local-file:///var/storage/secattach/20260702/26729341.html

Form 4 Edesa Biotech, Inc. For: Jul 02 Filed by: Nijhawan Pardeep

Thu, 02 Jul 2026 17:06:00 -0400

si-local-file:///var/storage/secattach/20260702/26729341.html

Form S-3 Edesa Biotech, Inc.

Thu, 02 Jul 2026 17:01:00 -0400

si-local-file:///var/storage/secattach/20260702/26729222.html

Form S-3 Edesa Biotech, Inc.

Thu, 02 Jul 2026 17:01:00 -0400

si-local-file:///var/storage/secattach/20260702/26729222.html

Brookline Capital Markets Starts Edesa Biotech Inc. (EDSA) at Buy

Mon, 29 Jun 2026 15:27:37 -0400

Brookline Capital Markets analyst Kumaraguru Raja initiates coverage on Edesa Biotech Inc. (NASDAQ: EDSA) with a Buy rating and a price target of $21.00.

The analyst comments "Conclusions ─ We initiate coverage on Edesa Biotech with a Buy rating and a TP of $21. EB06, an anti-CXCL10 monoclonal antibody, is entering the clinic as a therapy for vitiligo, an autoimmune disorder that causes skin to lose its color in patches. CXCL10 has been shown to play a key role in vitiligo pathogenesis. EB01 (1.0% daniluromer cream), a topical sPLA2 inhibitor that targets the anti-inflammatory pathway upstream of where currently approved nonsteroidal

Brookline Capital Markets Starts Edesa Biotech Inc. (EDSA) at Buy

Mon, 29 Jun 2026 15:27:37 -0400

Brookline Capital Markets analyst Kumaraguru Raja initiates coverage on Edesa Biotech Inc. (NASDAQ: EDSA) with a Buy rating and a price target of $21.00.

Form D Edesa Biotech, Inc.

Fri, 26 Jun 2026 17:05:00 -0400

si-local-file:///var/storage/secattach/20260626/26699780.html

Form D Edesa Biotech, Inc.

Fri, 26 Jun 2026 17:05:00 -0400

si-local-file:///var/storage/secattach/20260626/26699780.html

Form SCHEDULE 13G Edesa Biotech, Inc. Filed by: INTEGRATED CORE STRATEGIES (US) LLC

Thu, 18 Jun 2026 17:06:00 -0400

si-local-file:///var/storage/secattach/20260618/26667149.html

Form SCHEDULE 13G Edesa Biotech, Inc. Filed by: INTEGRATED CORE STRATEGIES (US) LLC

Thu, 18 Jun 2026 17:06:00 -0400

si-local-file:///var/storage/secattach/20260618/26667149.html

Form SCHEDULE 13D/A Edesa Biotech, Inc. Filed by: Nijhawan Pardeep

Tue, 16 Jun 2026 17:07:00 -0400

si-local-file:///var/storage/secattach/20260616/26655154.html

Form SCHEDULE 13D/A Edesa Biotech, Inc. Filed by: Nijhawan Pardeep

Tue, 16 Jun 2026 17:07:00 -0400

si-local-file:///var/storage/secattach/20260616/26655154.html

Form 4 Edesa Biotech, Inc. For: Jun 16 Filed by: Nijhawan Pardeep

Tue, 16 Jun 2026 17:03:00 -0400

si-local-file:///var/storage/secattach/20260616/26655114.html

Form 4 Edesa Biotech, Inc. For: Jun 16 Filed by: Nijhawan Pardeep

Tue, 16 Jun 2026 17:03:00 -0400

si-local-file:///var/storage/secattach/20260616/26655114.html

Form 8-K Edesa Biotech, Inc. For: Jun 10

Thu, 11 Jun 2026 09:20:00 -0400

si-local-file:///var/storage/secattach/20260611/26633585.html

Form 8-K Edesa Biotech, Inc. For: Jun 10

Thu, 11 Jun 2026 09:20:00 -0400

si-local-file:///var/storage/secattach/20260611/26633585.html

Edesa Biotech raises $3.5 million in private placement led by CEO

Thu, 11 Jun 2026 09:15:25 -0400

Edesa Biotech Inc. (NASDAQ: EDSA) announced it entered into a securities purchase agreement for a private investment in public equity financing expected to generate gross proceeds of approximately $3.5 million before deducting offering expenses.

The clinical-stage biopharmaceutical company sold 729,241 common shares in the private placement. Investors paid $4.69 per share, while the company's chief executive officer paid $5.21 per share. The financing was completed without an agent, underwriter, broker or dealer.

Participants in the financing include Edesa's CEO and healthcare-focused investors. The transaction is expected to close on or about June 15, 2026, subject to customary closing conditions.

The company stated it

Edesa Biotech raises $3.5 million in private placement led by CEO

Thu, 11 Jun 2026 09:15:25 -0400

Participants in the financing include Edesa's CEO and healthcare-focused investors. The transaction is expected to close on or about June 15, 2026, subject to customary closing conditions.

The company stated it

Edesa Biotech Announces $3.5 Million Private Placement of Common Shares Led by CEO and Healthcare-Focused Investors

Thu, 11 Jun 2026 09:15:00 -0400

TORONTO, June 11, 2026 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq: EDSA) (the “Company” or “Edesa”), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today announced that it has entered into a securities purchase agreement for a private investment in public equity (“PIPE”) financing that is expected to result in gross proceeds of approximately $3.5 million to the Company, before deducting offering expenses payable by Edesa. The common shares were placed without an agent, underwriter, broker or dealer. Investors in the PIPE include Edesa’s Chief Executive Officer and healthcare-focused investors. The PIPE is

Edesa Biotech Announces $3.5 Million Private Placement of Common Shares Led by CEO and Healthcare-Focused Investors

Thu, 11 Jun 2026 09:15:00 -0400

Edesa Biotech Announces $3.5 Million Private Placement of Common Shares Led by CEO and Healthcare-Focused Investors

Thu, 11 Jun 2026 09:15:00 -0400